FENC

FENNEC PHARMACEUTICALS INC. FENC

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #2,155 of 2,925

Why it scores 39Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$17.87M

Quarter to Jun 30

Net income

$1.97M

Quarter to Jun 30

Operating margin

9.7%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$175.07M total
Rosalind Advisors, Inc.
$34.27M+9.6%
AIGH Capital Management LLC
$26.72M+25.5%
Solas Capital Management, LLC
$20.31M-23.9%
BlackRock, Inc.
$18.57M+26.2%
AWM Investment Company, Inc.
$12.47M+61.1%
VANGUARD CAPITAL MANAGEMENT LLC
$9.02M-6.4%
Prospect Capital Advisors, LLC
$5.35MNew
STATE STREET CORP
$4.58M+18.6%
GEODE CAPITAL MANAGEMENT, LLC
$4.33M+8.3%
JANE STREET GROUP, LLC
$2.51MNew
Potomac Capital Management, Inc.
$2.41M0.0%
MORGAN STANLEY
$2.39M+5.1%
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.15M+18.7%
NORTHERN TRUST CORP
$1.81M+10.4%
MARSHALL WACE, LLP
$1.49MNew
RENAISSANCE TECHNOLOGIES LLC
$1.44MNew
Nuveen, LLC
$1.41M+115.7%
Trexquant Investment LP
$1.28M+129.7%
CenterBook Partners LP
$1.27MNew
Lion Point Capital, LP
$1.21M0.0%
BRIDGEWAY CAPITAL MANAGEMENT, LLC
$1.16M+30.1%
Cornerstone Capital, Inc.
$1.13M0.0%
XTX Topco Ltd
$1.01M+515.3%
AQR CAPITAL MANAGEMENT LLC
$998.6K+284.7%
WELLINGTON MANAGEMENT GROUP LLP
$908.9KNew
See all 106 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Operating Margin

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/FENC

Earnings Per Share

13fpro.ai/company/FENC

Loading ratio trend…

FENC key financials by period

Reported revenue, net income and operating margin by fiscal year, from FENNEC PHARMACEUTICALS INC.'s annual filings on SEC EDGAR.

FENNEC PHARMACEUTICALS INC. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$44.6M$-9.7M-14.1%
FY 2024$47.5M$-436.0K5.4%
FY 2023$21.3M$-16.0M-60.1%
FY 2022$1.5M$-23.7M—
FY 2020$170.0K$-18.1M—
Source: FENC filings on SEC EDGAR →

Companies similar to FENC

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

FENC insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About FENNEC PHARMACEUTICALS INC. (FENC): stock profile, AI score and financials

FENNEC PHARMACEUTICALS INC. (FENC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FENC at 39.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,155 of 2,925 stocks — the bottom half of the AI-ranked universe. FENC scores in the top quartile across revenue growth (94.0). Areas of concern include revenue scale (10.6) and free cash flow (21.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), FENNEC PHARMACEUTICALS INC. reports quarterly revenue of $17.9M, net income of $2.0M, an operating margin of 9.7%. Top institutional holders of FENC by reported 13-F value include Rosalind Advisors, AIGH Capital Management, Solas Capital Management, based on the most recent SEC filings. FENC trades on the Nasdaq exchange and files with the SEC under CIK 1211583. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FENC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FENNEC PHARMACEUTICALS INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1211583 →